Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ProMIS Neurosciences ( (PMN) ) has provided an announcement.
On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a year-long period of non-compliance, during which the company was granted additional time to meet the requirement, ultimately achieving the necessary bid price through strategic measures such as a potential reverse stock split.
The most recent analyst rating on (PMN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences Inc. operates in the biotechnology industry, focusing on the development of therapeutic solutions for neurodegenerative diseases.
Average Trading Volume: 31,362
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.35M
Learn more about PMN stock on TipRanks’ Stock Analysis page.